These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35957721)

  • 41. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma.
    Song X; Wang S; Li J; Yan L; Chen F; Wang J
    Arch Med Sci; 2021; 17(5):1317-1324. PubMed ID: 34522261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials.
    Chen YP; Tang LL; Yang Q; Poh SS; Hui EP; Chan ATC; Ong WS; Tan T; Wee J; Li WF; Chen L; Ma BBY; Tong M; Tan SH; Cheah SL; Fong KW; Sommat K; Soong YL; Guo Y; Lin AH; Sun Y; Hong MH; Cao SM; Chen MY; Ma J
    Clin Cancer Res; 2018 Apr; 24(8):1824-1833. PubMed ID: 29431618
    [No Abstract]   [Full Text] [Related]  

  • 44. Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study.
    Li PJ; Lai YL; He F; Chen YY; Gu ZS; Luo W; Zhang Q
    Front Pharmacol; 2021; 12():688528. PubMed ID: 34621166
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma.
    Weng JJ; Wei JZ; Li M; Lu JL; Qin YD; Jiang H; Qu SH
    Cancer Med; 2020 Jan; 9(2):541-551. PubMed ID: 31774249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis.
    Bongiovanni A; Vagheggini A; Fausti V; Mercatali L; Calpona S; Di Menna G; Miserocchi G; Ibrahim T
    Crit Rev Oncol Hematol; 2021 Apr; 160():103244. PubMed ID: 33582249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
    Wu LR; Jiang XS; Song X; Yu HL; Fan YX; Wang FJ; Huang SF; Guo WJ; He X; Liu JY
    Oncotarget; 2017 Oct; 8(45):79953-79963. PubMed ID: 29108377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma.
    Xu YC; Chen KH; Liang ZG; Zhu XD
    Front Oncol; 2022; 12():843675. PubMed ID: 35903695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Feasibility and efficiency of double-agent versus single-agent concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
    Qin G; Rai R; Zhang R; Su Y; Zhang B; Pan Y; Xiong R; Xie Y; Yang H; Kong X; Luo Z; Ruan X; Mo Y; Aftab O; Shahisanjeev ; Jazib ; Jiang W
    Oral Oncol; 2020 Jul; 106():104704. PubMed ID: 32330685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stratification of Candidates for Induction Chemotherapy in Stage III-IV Nasopharyngeal Carcinoma: A Large Cohort Study Based on a Comprehensive Prognostic Model.
    Sun XS; Xiao BB; Lu ZJ; Liu SL; Chen QY; Yuan L; Tang LQ; Mai HQ
    Front Oncol; 2020; 10():255. PubMed ID: 32185130
    [No Abstract]   [Full Text] [Related]  

  • 54. Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases.
    Ou X; Xu T; He X; Ying H; Hu C
    J Cancer; 2017; 8(14):2836-2845. PubMed ID: 28928873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
    Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
    Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis.
    Zhang B; Li MM; Chen WH; Zhao JF; Chen WQ; Dong YH; Gong X; Chen QY; Zhang L; Mo XK; Luo XN; Tian J; Zhang SX
    JAMA Netw Open; 2019 Oct; 2(10):e1913619. PubMed ID: 31626318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
    Xu C; Chen YP; Liu X; Li WF; Chen L; Mao YP; Zhang Y; Guo R; Zhou GQ; Tang LL; Lin AH; Sun Y; Ma J
    Oral Oncol; 2017 Jun; 69():99-107. PubMed ID: 28559028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
    You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
    Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020.
    Liang YJ; Liu LT; Li Y; Wang P; Luo MJ; Wen DX; Chen QY; Mai HQ
    JAMA Netw Open; 2022 Mar; 5(3):e220173. PubMed ID: 35234882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era.
    Su Z; Zou GR; Tang J; Li XY; Xie FY
    Ther Clin Risk Manag; 2020; 16():201-211. PubMed ID: 32280230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.